Literature DB >> 7632510

Vitamin D metabolites in childhood nephrotic syndrome.

A Grymonprez1, W Proesmans, M Van Dyck, I Jans, G Goos, R Bouillon.   

Abstract

We measured serum levels of total and ionised calcium, phosphate, intact parathyroid hormone, 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1,25(OH)2D] and the vitamin D binding protein (DBP) in 14 children with idiopathic nephrotic syndrome and 10 healthy, age-matched controls. In all nephrotics serum DBP levels were below the normal range. Serum 25(OH)D was below 7 ng/ml in 10 of 14 nephrotic children and in the low normal range in the remaining 4 patients. The average serum 1,25(OH)2D levels were lower in the nephrotic patients than in the controls. However, free 1,25(OH)2D levels were normal in the nephrotic patients. Both serum 25(OH)D and 1,25(OH)2D correlated positively with the concentration of DBP. There was a significant negative correlation between serum DBP levels and the urinary protein excretion and a significant positive correlation between the urinary excretions of DBP and albumin. From this study it can be concluded that the nephrotic child is capable of maintaining appropriate serum concentrations of free calcitriol despite important urinary losses of both substrate and bound calcitriol.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7632510     DOI: 10.1007/bf02254183

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  18 in total

1.  Measurement of 25-hydroxyvitamin D3 in serum.

Authors:  R Bouillon; P V Kerkhove; P De Moor
Journal:  Clin Chem       Date:  1976-03       Impact factor: 8.327

2.  CALCIUM METABOLISM IN NEPHROSIS. I. A DESCRIPTION OF AN ABNORMALITY IN CALCIUM METABOLISM IN CHILDREN WITH NEPHROSIS.

Authors:  K Emerson; W W Beckman
Journal:  J Clin Invest       Date:  1945-07       Impact factor: 14.808

3.  Serum ionized calcium in nephrotic syndrome.

Authors:  P Lim; E Jacob; L F Chio; H S Pwee
Journal:  Q J Med       Date:  1976-07

4.  Blood levels of 25-hydroxyvitamin D in nephrotic syndrome. Studies in 26 patients.

Authors:  D A Goldstein; Y Oda; K Kurokawa; S G Massry
Journal:  Ann Intern Med       Date:  1977-12       Impact factor: 25.391

5.  Transport of vitamin D: significance of free and total concentrations of the vitamin D metabolites.

Authors:  R Bouillon; H Van Baelen
Journal:  Calcif Tissue Int       Date:  1981       Impact factor: 4.333

6.  Absence of metabolic bone disease in adult patients with the nephrotic syndrome and normal renal function.

Authors:  A Korkor; J Schwartz; M Bergfeld; S Teitelbaum; L Avioli; S Klahr; E Slatopolsky
Journal:  J Clin Endocrinol Metab       Date:  1983-03       Impact factor: 5.958

7.  Calcium and vitamin D metabolism in children with nephrotic syndrome.

Authors:  M Freundlich; J J Bourgoignie; G Zilleruelo; C Abitbol; J M Canterbury; J Strauss
Journal:  J Pediatr       Date:  1986-03       Impact factor: 4.406

8.  Vitamin-D metabolism in nephrotic syndrome.

Authors:  J M Barragry; M W France; N D Carter; J A Auton; M Beer; B J Boucher; R D Cohen
Journal:  Lancet       Date:  1977-09-24       Impact factor: 79.321

9.  Studies on vitamin D binding protein in the nephrotic syndrome.

Authors:  K Colston; N J Williams; H J Cleeve
Journal:  Clin Chem       Date:  1985-05       Impact factor: 8.327

10.  Decreased free 1,25-dihydroxycholecalciferol index in patients with the nephrotic syndrome.

Authors:  J Auwerx; L De Keyser; R Bouillon; P De Moor
Journal:  Nephron       Date:  1986       Impact factor: 2.847

View more
  29 in total

1.  Ethnic differences in 25-hydroxyvitamin D levels and response to treatment in CKD.

Authors:  Iris Sanchez; Roberto Mangoo-Karim; Jason R Stubbs; George P Yanev; James B Wetmore
Journal:  Int Urol Nephrol       Date:  2012-05-30       Impact factor: 2.370

2.  Vitamin D metabolites in childhood nephrotic syndrome.

Authors:  U S Alon
Journal:  Pediatr Nephrol       Date:  1995-12       Impact factor: 3.714

3.  Free vitamin D levels in steroid-sensitive nephrotic syndrome and healthy controls.

Authors:  Sushmita Banerjee; Surupa Basu; Shakil Akhtar; Rajiv Sinha; Ananda Sen; Jayati Sengupta
Journal:  Pediatr Nephrol       Date:  2019-12-16       Impact factor: 3.714

4.  Disease activity, proteinuria, and vitamin D status in children with systemic lupus erythematosus and juvenile dermatomyositis.

Authors:  Angela Byun Robinson; Myrtle Thierry-Palmer; Keisha L Gibson; Consuelo Egla Rabinovich
Journal:  J Pediatr       Date:  2011-09-15       Impact factor: 4.406

5.  The effect of vitamin D and calcium supplementation in pediatric steroid-sensitive nephrotic syndrome.

Authors:  Sushmita Banerjee; Surupa Basu; Ananda Sen; Jayati Sengupta
Journal:  Pediatr Nephrol       Date:  2017-07-19       Impact factor: 3.714

6.  Glucocorticoid effects on changes in bone mineral density and cortical structure in childhood nephrotic syndrome.

Authors:  Anne Tsampalieros; Pooja Gupta; Michelle R Denburg; Justine Shults; Babette S Zemel; Sogol Mostoufi-Moab; Rachel J Wetzsteon; Rita M Herskovitz; Krista M Whitehead; Mary B Leonard
Journal:  J Bone Miner Res       Date:  2013-03       Impact factor: 6.741

7.  Vitamin D in nephrotic syndrome remission: a case-control study.

Authors:  Sushmita Banerjee; Surupa Basu; Jayati Sengupta
Journal:  Pediatr Nephrol       Date:  2013-05-25       Impact factor: 3.714

8.  Biochemical bone markers in nephrotic children.

Authors:  Nese Karaaslan Biyikli; Sevinc Emre; Aydan Sirin; Ilmay Bilge
Journal:  Pediatr Nephrol       Date:  2004-06-17       Impact factor: 3.714

9.  Growth in steroid-responsive nephrotic syndrome: a study of 85 pediatric patients.

Authors:  Teresinha L Donatti; Vera H Koch; Maria D Fujimura; Yassuhiko Okay
Journal:  Pediatr Nephrol       Date:  2003-05-16       Impact factor: 3.714

10.  Vitamin D binding protein genotype and osteoporosis.

Authors:  Yue Fang; Joyce B J van Meurs; Pascal Arp; Johannes P T van Leeuwen; Albert Hofman; Huibert A P Pols; André G Uitterlinden
Journal:  Calcif Tissue Int       Date:  2009-06-02       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.